MedWatch

Demant expects medium to long-term revenue growth of 7-10 percent

Prior to the company's capital markets day, the hearing aid group Demant unveils management's medium and long-term visions.

Photo: Demant / PR

Demant is waiting for pent-up hearing aid demand to support unit sales on the hearing aid market in the coming years. The hearing aid manufacturer is also expecting to generate an annual revenue growth of 7-10 percent in the medium and long term, the company writes in a statement just prior to its capital markets day on Monday.

Organic growth is further estimated to increase by 6-8 percent in the same period, supplemented by 1-2 percent coming from acquisitions.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs